Rapid Development Of Amorphous Solid Dispersions For Improved Bioavailability

Source: Lonza

A growing number of drugs in the development pipeline are poorly soluble in gastrointestinal fluids, and can severely limit oral bioavailability. This talk describes how an amorphous solid dispersion (ASD) of acalabrutinib was designed using in vitro studies and in silico modeling. Watch now to understand how ASD formulations can enhance bioavailability.

access the Webinar!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Drug Delivery Leader? Subscribe today.

Subscribe to Drug Delivery Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Drug Delivery Leader